Ocuphire Pharma Inc - ESG Rating & Company Profile powered by AI
This webpage of Ocuphire Pharma Inc is prepared by All Street Sevva using cutting edge Cognitive Robots. The Sustainability score for Ocuphire Pharma Inc indicates its reporting of the UN Sustainable Development Goals. The Disclosure score includes seventeen UN Sustainable Development Goals including: 'Quality Education', 'Reduced Inequalities' and 'Partnerships for the Goals'.
Ocuphire Pharma Inc in the Pharmaceuticals industry gained a UN SDG ESG Transparency Score of 5.3; made up of an environmental score of 6.0, social score of 5.3 and governance score of 4.6.
5.3
Medium ImpactEnvironmental
Social
Governance
Peer Group Comparison
| Rank | Company | SDG Transparency Score ⓘ | Performance |
|---|---|---|---|
| 1 | Novartis AG | 9.2 | High |
| 2 | Daiichi Sankyo Co Ltd | 8.9 | High |
| 886 | Veracyte Inc | 5.4 | High |
| 886 | Xlife Sciences AG | 5.4 | High |
| 912 | Ocuphire Pharma Inc | 5.3 | High |
| 912 | Acer Therapeutics Inc | 5.3 | High |
| 912 | Alembic Pharmaceuticals Ltd | 5.3 | High |
| ... | ... | ... | |
| 2749 | Xynomic Pharmaceuticals Holdings Inc | 0.0 | Low |
| 2749 | Zyden Gentec Ltd | 0.0 | Low |
| ... | ... | ... |
Frequently Asked Questions
Does Ocuphire Pharma Inc have an accelerator or VC vehicle to help deliver innovation?
Sign up for free to unlockDoes Ocuphire Pharma Inc disclose current and historical energy intensity?
Sign up for free to unlockDoes Ocuphire Pharma Inc report the average age of the workforce?
Sign up for free to unlockDoes Ocuphire Pharma Inc reference operational or capital allocation in relation to climate change?
Sign up for free to unlockDoes Ocuphire Pharma Inc disclose its ethnicity pay gap?
Sign up for free to unlockDoes Ocuphire Pharma Inc disclose cybersecurity risks?
Sign up for free to unlockDoes Ocuphire Pharma Inc offer flexible work?
Sign up for free to unlockDoes Ocuphire Pharma Inc have a long term incentive (LTI) executive compensation plan based on a measure of return on capital?
Sign up for free to unlockDoes Ocuphire Pharma Inc disclose the number of employees in R&D functions?
Sign up for free to unlockDoes Ocuphire Pharma Inc conduct supply chain audits?
Sign up for free to unlockDoes Ocuphire Pharma Inc disclose incidents of non-compliance in relation to the health and safety impacts of products and services?
Sign up for free to unlockIs there a statment that there is no plan to expand their cement production? (for example: 'We have no current plans to add additional cement making capacity')
Sign up for free to unlockDoes Ocuphire Pharma Inc conduct 360 degree staff reviews?
Sign up for free to unlockDoes Ocuphire Pharma Inc disclose the individual responsible for D&I?
Sign up for free to unlockDoes Ocuphire Pharma Inc disclose current and historical air emissions?
Sign up for free to unlockIs there a statment that there is no plan to expand their coal usage? (for example: 'We have no current plans to add additional coal powered electricity generation')
Sign up for free to unlockIs executive remuneration linked to climate performance?
Sign up for free to unlockDoes the Board describe its role in the oversight of climate-related risks and opportunities?
Sign up for free to unlockDoes Ocuphire Pharma Inc disclose current and / or historical scope 2 emissions?
Sign up for free to unlockDoes Ocuphire Pharma Inc disclose water use targets?
Sign up for free to unlockDoes Ocuphire Pharma Inc have careers partnerships with academic institutions?
Sign up for free to unlockDid Ocuphire Pharma Inc have a product recall in the last two years?
Sign up for free to unlockDoes Ocuphire Pharma Inc disclose incidents of discrimination?
Sign up for free to unlockDoes Ocuphire Pharma Inc allow for Work Councils/Collective Agreements to be formed?
Sign up for free to unlockHas Ocuphire Pharma Inc issued a profit warning in the past 24 months?
Sign up for free to unlockDoes Ocuphire Pharma Inc disclose parental leave metrics?
Sign up for free to unlockDoes Ocuphire Pharma Inc disclose climate scenario or pathway analysis?
Sign up for free to unlockDoes Ocuphire Pharma Inc disclose current and / or historical scope 1 emissions?
Sign up for free to unlockAre Operating Expesnses linked to emissions reduction?
Sign up for free to unlockDoes Ocuphire Pharma Inc disclose the pay ratio of women to men?
Sign up for free to unlockDoes Ocuphire Pharma Inc support suppliers with sustainability related research and development?
Sign up for free to unlockDoes Ocuphire Pharma Inc disclose the number of operations that have been subject to human rights reviews or human rights impact assessments?
Sign up for free to unlockDoes Ocuphire Pharma Inc reflect climate-related risks in its financial statements?
Sign up for free to unlockIs there a statment that there is no plan to expand their carbon intensite energy assets? (for example: 'We have no current plans to carry out further drilling for oil,')
Sign up for free to unlockIs Ocuphire Pharma Inc involved in embryonic stem cell research?
Sign up for free to unlockDoes Ocuphire Pharma Inc disclose GHG and Air Emissions intensity?
Sign up for free to unlockDoes Ocuphire Pharma Inc disclose its waste policy?
Sign up for free to unlockDoes Ocuphire Pharma Inc report according to TCFD requirements?
Sign up for free to unlockDoes Ocuphire Pharma Inc disclose its policies for bribery, corruption, whistle-blower, conflict of interest?
Sign up for free to unlockDoes Ocuphire Pharma Inc disclose energy use targets?
Sign up for free to unlockDoes Ocuphire Pharma Inc disclose its Renewable Energy targets?
Subscription requiredAre emissions metrics verified by STBi?
Subscription requiredDoes Ocuphire Pharma Inc have a policy relating to cyber security?
Sign up for free to unlockHave a different question?
Potential Risks for Ocuphire Pharma Inc
These potential risks are based on the size, segment and geographies of the company.
Ocuphire Pharma, Inc., a clinical-stage ophthalmic biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of refractive and retinal eye disorders. Its lead product candidate is Nyxol eye drops, a once-daily preservative-free eye drop formulation of phentolamine mesylate, which is in Phase III clinical trial for dim light or night vision disturbances; and Phase 2b clinical trial for pharmacologically induced mydriasis, as well as that has completed Phase 2 VEGA-1 trial for presbyopia. The company also develops APX3330, a twice-a-day oral tablet to target pathways relevant to retinal and choroidal vascular diseases, such as diabetic retinopathy and diabetic macular edema; and APX2009 and APX2014 second generation preclinical product candidates and analogs of APX3330. Ocuphire Pharma, Inc. is headquartered in Farmington Hills, Michigan.